[Clinical experience in treatment with the long-term insulin analogue glargin in a diabetes centre]

Related Experiment Video

Updated: Jul 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

I Haladová1, S Lacigová, Z Jankovec

  • 1Diabetologické centrum I. interní kliniky Lékarské fakulty UK a FN Plzen. Haladovai@fnplzen.cz

Vnitrni Lekarstvi
|August 19, 2007
PubMed

Insights

Insulin glargine significantly improved glycemic control and reduced blood sugar variability in type 1 diabetes patients. This long-acting insulin analogue demonstrated effectiveness without altering basal insulin doses.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacotherapy

Background:

  • Type 1 diabetes mellitus (DM) management requires effective glycemic control.
  • Long-term insulin analogues offer potential improvements in diabetes management.

Purpose of the Study:

  • To evaluate the clinical experience with insulin glargine in type 1 diabetes patients.
  • To assess the impact of insulin glargine on glycemic control and variability.

Main Methods:

  • Retrospective analysis of 136 type 1 DM patients over one year.
  • Monitoring of HbA1c levels at baseline and at 3, 6, and 12 months post-treatment.
  • Comparison of glycemic variability using standard deviation of glucose readings before and after glargine therapy.

Main Results:

  • Significant reduction in HbA1c from 7.4% to 7.1% after one year (p < 0.01).
  • Marked decrease in glycemic variability (standard deviation) from 4.9 to 4.5 mmol/l (p < 0.001).
  • Reduction in total daily insulin dose and bolus insulin dose, with no change in basal dose.

Conclusions:

  • Insulin glargine treatment leads to significant improvements in HbA1c and glycemic variability.
  • The daily dose of insulin glargine is comparable to NPH insulin.
  • Insulin glargine is an effective therapeutic option for type 1 diabetes management.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...